November 28, 2016 - By Darrin Black · 0 Comments
The stock of Biondvax Pharmaceuticals Limited Ads (NASDAQ:BVXV) registered a decrease of 12.07% in short interest. BVXV’s total short interest was 20,400 shares in November as published by FINRA. Its down 12.07% from 23,200 shares, reported previously. With 2,200 shares average volume, it will take short sellers 9 days to cover their BVXV’s short positions. The short interest to Biondvax Pharmaceuticals Limited Ads’s float is 0.63%. About 642 shares traded hands. BiondVax Pharmaceuticals Ltd (ADR) (NASDAQ:BVXV) has declined 12.88% since April 25, 2016 and is downtrending. It has underperformed by 18.89% the S&P500.
BiondVax Pharmaceuticals Ltd is an Israel biopharmaceutical company. The company has a market cap of $11.65 million. The Firm holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. It has a 114 P/E ratio. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains.
Another recent and important BiondVax Pharmaceuticals Ltd (ADR) (NASDAQ:BVXV) news was published by Benzinga.com which published an article titled: “IPO Outlook: Galapagos Offers New Hope For CF And RA Sufferers” on May 12, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black